ProCE Banner Activity

Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors

Slideset Download
Get up to date on the use of newly approved and emerging PARP inhibitors for the treatment of patients with metastatic CRPC and DNA repair defects. Includes a case study!

Released: July 09, 2020

Expiration: July 08, 2021

No longer available for credit.

Share

Faculty

Celestia S. Higano

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California